Vedanta Biosciences, Inc.

Charting a New World of Medicines

Vedanta is a clinical-stage biopharmaceutical company pioneering the development of defined bacterial consortia as oral therapies that modulate the human microbiome to treat disease. Its pipeline includes product candidates for C. difficile infection, inflammatory bowel disease, Gram-negative infections, solid tumors, and food allergy.

Program Indication Funding MOA Preclinical cmc Phase 1 Phase 2 Phase 3 Rights
VE303 C. difficile
Preclinical Phase complete
cmc Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
VE202 Inflammatory Bowel Disease
Preclinical Phase complete
cmc Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
VE800 Solid Tumors
in combination with nivolumab (Opdivo)
Preclinical Phase complete
cmc Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
VE707 Gram-negative Infections
Preclinical Phase complete
cmc Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Investigator Sponsored Trials VE416 Food Allergy
in combination with immunotherapy
Preclinical Phase complete
cmc Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
VE303 Hepatic Encephalopathy
Preclinical Phase complete
cmc Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started

MOA: Mechanism of Action; CMC; Chemistry, Manufacturing and Controls

Colonization
resistance

Immuno -
regulation

Immuno -
potentiation

Our Partners

We aim to collaborate with partners to advance bacterial consortia therapeutics either through direct licensing of our products or our intellectual property.

We also collaborate with clinical and academic institutions to learn from human interventional studies and to further our mechanistic understanding of bacterial consortia therapeutics.

View Partnerships

The Leading Platform for Development of Bacterial Consortia Therapeutics

Our discovery platform enables identification of bacterial consortia with drug-like properties and their manufacture to GMP standards.

How Our Proprietary Discovery Platform Works